本文關(guān)鍵詞：復(fù)星醫(yī)藥海外并購績效分析及啟示　出處：《首都經(jīng)濟貿(mào)易大學(xué)》2017年碩士論文　論文類型：學(xué)位論文

  更多相關(guān)文章： 跨國并購 并購績效 協(xié)同效應(yīng)

【摘要】：進入21世紀以來,隨著我國經(jīng)濟的快速增長,我國在全球經(jīng)濟中的地位逐漸提高,我國醫(yī)藥市場也成為僅次于美國的全球第二大醫(yī)藥市場。我國部分醫(yī)藥企業(yè)也逐步走向國際市場,開始在全球布局。最近幾年,隨著醫(yī)藥企業(yè)海外并購事件不斷涌現(xiàn),人們越來越關(guān)注海外并購能不能創(chuàng)造價值,以及跨國并購行為對企業(yè)經(jīng)營績效的影響。復(fù)星醫(yī)藥上市公司是通過投資并購發(fā)展起來的,其在成長過程中進行過多次國內(nèi)外并購,對跨國并購積累了豐富經(jīng)驗。復(fù)星醫(yī)藥在2016年又耗費14億美元收購印度GLAND公司。到底是什么原因在導(dǎo)致復(fù)星醫(yī)藥不停地進行海外并購。這背后到底蘊含著什么意義?并購是否能夠給企業(yè)創(chuàng)造價值。本文以復(fù)星醫(yī)藥并購以色列Alma公司為案例進行分析,討論并購的原因與整合效果。在此基礎(chǔ)上,進一步分析這一成功案例能夠為我國醫(yī)藥企業(yè)海外并購和戰(zhàn)略整合提供相關(guān)經(jīng)驗和啟示。
[Abstract]:Since entering twenty-first Century, with the rapid growth of China's economy, China's position in the global economy has been improving. China's pharmaceutical market has become the second largest pharmaceutical market in the world after the US. Some of the pharmaceutical enterprises in China are gradually moving towards the international market and began to be distributed globally. In recent years, with the emergence of overseas mergers and acquisitions of pharmaceutical companies, people pay more and more attention to whether overseas mergers and acquisitions can create value and the impact of cross-border M & A on business performance. Fosun Pharmaceutical Listed Company has been developed through investment merger and acquisition. It has made many domestic and foreign acquisitions during its growth, and has accumulated rich experience in cross-border mergers and acquisitions. In 2016, Fosun medicine spent 1 billion 400 million dollars to buy India GLAND. What is the reason for the continued overseas merger and acquisition of Fuxing medicine. What is the meaning behind this? Whether M & A can create value for the enterprise. This paper analyzes the case of the merger and acquisition of Alma in Israel, and discusses the reasons for the merger and the effect of the integration. On this basis, the further analysis of this successful case can provide some experience and inspiration for the overseas merger and strategic integration of Chinese pharmaceutical enterprises.
【學(xué)位授予單位】：首都經(jīng)濟貿(mào)易大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：F426.72;F271

【相似文獻】

相關(guān)期刊論文 前10條

1 陳少瑜,鄭清;中國企業(yè)怎么“走出去”[J];政策w，

本文編號：1339523